Last reviewed · How we verify

NCT06969755: BEEST

Biomarkers to Enhance Early Schizophrenia Treatment

Not yet recruiting Phase 4 Last updated 14 May 2025
What this trial tests

Phase 4 trial testing aripiprazole in Schizophenia Disorder in 180 participants. Not yet recruiting.

Timeline
30 July 2025
Primary endpoint
30 July 2030
30 July 2030

Quick facts

Lead sponsorNorthwell Health
PhasePhase 4
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment180
Start date30 July 2025
Primary completion30 July 2030
Estimated completion30 July 2030
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Northwell Health — full company profile →

Who can join

Adults 18 to 35, any sex, with Schizophenia Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of aripiprazole

Trials testing the same drug.

Other recruiting trials for Schizophenia Disorder

Currently open trials in the same condition.

Other Northwell Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06969755.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing